Related Experiment Video
Updated: Jan 4, 2026
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
NUT midline carcinoma: Current concepts and future perspectives of a novel tumour entity
Massimiliano Salati1, Cinzia Baldessari2, Luca Reggiani Bonetti3
1Department of Oncology, University of Modena e Reggio Emilia, Modena Cancer Centre, Modena, Italy; PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Italy.
Abstract:
NMC is a recently recognized cancer type hallmarked by chromosomal translocation involving the NUT gene, a catastrophic event leading to fusion oncoprotein responsible for malignant transformation and tumor progression. The aggressiveness of disease together with a poor response to conventional treatment make NMC one of the most lethal cancer. Moreover, although until recently NMC has been poorly understood and largely neglected, the number of reported cases is steadily rising. Recently, in addition to its pathogenetic and diagnostic role, NUT-fusion oncoprotein has been shown to be amenable to targeted inhibition using BET inhibitors. Future clinical trials are warranted with the aim of investigate the incorporation of targeted agent into multimodal therapeutic strategy. Since new promising NUT-targeting drugs are emerging that may affect the clinical course, the correct and prompt recognition of NMC is key to improve patients' outcome.
Insights
Nut midline carcinoma (NMC) is a lethal, aggressive cancer driven by NUT gene fusions. Targeted therapies like BET inhibitors show promise for this rare but rising cancer, necessitating prompt diagnosis for better patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Nut midline carcinoma (NMC) is a rare but aggressive cancer characterized by NUT gene rearrangements.
- The resulting fusion oncoprotein drives malignant transformation and tumor progression.
- NMC exhibits poor response to conventional therapies, contributing to its high lethality.
Purpose of the Study:
- To highlight the pathogenetic role of NUT-fusion oncoprotein in NMC.
- To discuss the emerging therapeutic strategies targeting NUT-fusion oncoprotein.
- To emphasize the importance of early and accurate NMC diagnosis.
Main Methods:
- Review of recent scientific literature on NMC.
- Analysis of the role of NUT-fusion oncoprotein in cancer development.
- Evaluation of targeted therapies, specifically BET inhibitors.
Main Results:
- NUT-fusion oncoprotein is central to NMC pathogenesis and a target for therapy.
- BET inhibitors demonstrate potential for targeted inhibition of NUT-fusion oncoprotein.
- The number of reported NMC cases is increasing, indicating a need for greater awareness.
Conclusions:
- Prompt recognition and diagnosis of NMC are crucial for improving patient outcomes.
- Targeted therapies, particularly BET inhibitors, offer new hope for NMC treatment.
- Future clinical trials should explore integrating targeted agents into multimodal therapeutic strategies for NMC.
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers